Sizeable growth potential for global drug delivery and packaging in 2019

19 Mar 2019

Patient-centricity, eco-friendly and smart packaging trends marked as the biggest growth drivers and innovations in 2019.

The drug delivery and healthcare packaging industry is set for significant growth in 2019 as Pharmapack Europe – a key bellwether of industry health – welcomed a record 410 exhibiting companies and nearly 5,500 attendees from 75 countries. Europe’s biggest pharmaceutical packaging and drug delivery event (Paris Expo, Porte de Versailles, France 6-7 February, 2019) saw a diversification of innovations and new drug delivery solutions, with ‘patient-centricity’ emerging as the central theme throughout this year’s edition.

Sizeable growth potential for global drug delivery and packaging in 2019

A who’s who of pharma packaging and delivery innovators exhibited at Pharmapack from BD and Baumann to Nemera, Aptar, SFM Medical Devices, SHL, Vetter and West Pharmaceutical Services. Beyond these global giants, the event also played host to some of the hottest emerging innovators in the Start-up hub – showcasing new technologies from AI development platforms and advanced data analytics to miniaturised packaging sensors, soft mist inhalers, and smart packaging.

Pharmapack is widely acknowledged as a window into upcoming industry trends with sustainability, eco-friendly packaging and smart packaging in particular earmarked for 2019. Highlighting renowned innovations, the Pharmapack Awards returned with a record number of entries, while the Innovation Gallery showcased a range of new technologies -from child-resistant pumps, and anti-tampering labels to connected and dual delivery devices, disposable autoinjectors and Augmented Reality on smartphones.

Environmental impact

The conference agenda explored major industry changes that lie ahead, including how to lower development costs while increasing sustainability. Gregor Anderson, Managing Director, Pharmacentric Solutions, suggested: “We could potentially further improve sustainability in device design and sourcing by working earlier with suppliers, so they can engineer out costs and environmental impact.” Anderson added that harnessing consumers' growing environmental conscience and asking them to return inhalers to a pharmacy after use for recycling could “deliver tremendous results when factoring in just how many inhalers are disposed of each year”.

Another green approach discussed at the event was replacing PVC in secondary packaging, and Yves Steffen, Head of Packaging & Devices in Biological Technical Development and Manufacturing at Novartis, expects an industry-wide change to ‘plastic neutral’.

But several of the sustainability panel’s experts also forewarned that primary packaging will remain a challenge, as it needs stability testing, which takes a long time to develop and implement. In particular, Guilhem Rousselet, Global Packaging & Serialization – Industrial Affairs at Sanofi added: “There is just not yet any industry solution to replace PVC as the material of choice – we are still some way off this”.

Connected devices and data

In a separate session on ‘what’s new in biologicals and biosimilar drug delivery devices’, experts agreed that technology is already there to collect data, but that the biggest potential hurdle is upscaling of new devices and issues around patient privacy. David Braun, Global Head of Medical Device and Digital Health Business solutions at Merck, postulated that the adoption rate of connected devices is slow due to ‘high costs, complicated GUIs and lack of patient awareness’. Experts forecast that ‘closed loop digitization’, such as heart monitoring is the future, and the biggest challenge will be managing the integrity of the data created.

Concerns around patient data were shared throughout the conference, with Alex Driver, Senior Consultant at Team Consulting, taking a particularly interesting angle on the situation. He believes that while people are concerned with how their data is being used, they still actively use connected devices, such as phones due to the value of the device outweighing potential concerns. He argues that if a patient is forgoing their privacy in order to use a connected device, healthcare companies simply need to incentivise patients to use the system by potentially shifting patient behaviour with optimum design.

Silvia Forroova, Brand Director at Pharmapack Europe commented: “This year’s event demonstrated what an exciting time it is for drug delivery and packaging. I anticipate many of the innovations seen on the show floor this week delivering improvements in patient care over the next few years – in particular those across patient-friendly and sustainable solutions. The conference agenda showed the depth and breadth of new developments and 2019 looks set to bring a golden age of patient-focused developments and innovations from smart packaging and connected devices to autoinjectors. Our agenda also highlighted the importance of partnering to bring newer innovations to market, meeting new contacts who can help scale-up promising technologies beyond clinical development and into commercial supply. This is why an event like Pharmapack remains so crucial to industry innovation moving forwards; it’s about meeting contacts, exchanging ideas and learning vital new skills to help further the industry so we can deliver new solutions for patients globally”.

Related news

Catalent extends global commercial spray drying capabilities in Europe

Catalent extends global commercial spray drying capabilities in Europe

9 Jul 2019

Company's customers to have immediate access to Niro PSD2 and PSD4 spray driers, which are supported by dedicated clean area facilities for both solvent and aqueous processing of potent or non-potent drug formulations.

Read more 
Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

18 Jun 2019

Industry leaders give voice to issues and trends shaping the biotech sector, including the importance of collaboration.

Read more 
Lessons learned from early EU FMD adopters

Lessons learned from early EU FMD adopters

13 May 2019

Data exchange, investment costs, resources and hardware identified as some of the biggest challenges.

Read more 
Brexit's trick or treat on patient safety

Brexit's trick or treat on patient safety

29 Apr 2019

Despite a delayed Brexit, unpredictability adds further complications to the EU FMD regulation.

Read more 
Surge of Indian biosimilars market forecast in 2019

Surge of Indian biosimilars market forecast in 2019

22 Apr 2019

India predicted to be one of the world’s ‘fastest growing bio’ hubs in 2019, fuelled by new biosimilars production.

Read more 
RAPS on delayed Brexit

RAPS on delayed Brexit

26 Mar 2019

The post-Brexit regulatory environment continues to weigh heavily on the minds of regulatory professionals.

Read more 
'Tamper-evident' benefits are evident

'Tamper-evident' benefits are evident

28 Feb 2019

2019 will mark Uniplast's debut at this year's edition of CPhI Worlwide in Frankfurt, where it will showcase its expertise in plastic packaging.

Read more 
All Recipharm facilities ready for EU serialisation, regardless of Brexit

All Recipharm facilities ready for EU serialisation, regardless of Brexit

15 Feb 2019

The CDMO invested EUR 35 million into its operations and launched a 3-year programme to provide a compliant serialisation solution for its customers.

Read more 
Brexit - the EU FMD's painful problem

Brexit - the EU FMD's painful problem

7 Feb 2019

Teething problems are no stranger to the implementation of new regulations, but with the EU FMD, Brexit came like a set of wisdom teeth – late, painful and problematic.

Read more 
Pharmapack report predicts diversification of innovation leading to a rise in licensing and partnering

Pharmapack report predicts diversification of innovation leading to a rise in licensing and partnering

27 Jan 2019

New report highlights Germany, France and Switzerland as tier-one nations for ‘drug delivery innovation’, and warns the challenge will be to scale-up and approve promising prototypes.

Read more